Table 4 Reasons for discontinuation of most common maintenance therapy.

From: Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database

Reasons for discontinuation

R/RD, n (%)

V/VD, n (%)

RV/RVD, n (%)

(n = 1614)

(n = 59)

(n = 36)

Progressive disease

544 (33.7)

28 (47.5)

21 (58.3)

No evidence of progressive disease

710 (44.0)

17 (28.8)

12 (33.3)

Toxicity

225 (13.9)

5 (8.5)

2 (5.6)

Patient refusal of treatment

24 (1.5)

0 (0)

1 (2.8)

Secondary malignancy

23 (1.4)

1 (1.7)

0 (0)

Death

19 (1.2)

2 (3.4)

0 (0)

Lost to follow up

41 (2.5)

0 (0)

0 (0)

Treatment completed

2 (0.1)

3 (5.1)

0 (0)

Doctors’ decision

8 (0.5)

2 (3.4)

0 (0)

Unknown

18 (1.2)

1 (1.7)

0 (0)

  1. R lenalidomide, D dexamethasone, V bortezomib.